Starna Therapeutics
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
Corporate information
- Company entity
- Starna Therapeutics
- Headquarters / principal office
- No verified public location identified
- Founded
- August 2021 ↗
- Ownership / capital status
- PrivatePrivately financed; Series B+ ↗
- Official corporate reference
- https://en.starnatx.com/ ↗
- Latest financing / award identified
- 2026-05-11 · Series B+ · Nearly US$40 million ↗
- LinkedIn company page
- Independent company page not verified
The announcement says nearly US$40 million; no exact numeric amount is asserted. This is separate from the October 2025 Series B reported in RMB.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Starna’s pipeline includes STR-P004 and STR-P005 in vivo CAR-T programs for autoimmune disease. An ASCO abstract describes CD19 CAR mRNA in CD8-targeted LNPs and exploratory patient dosing for STR-P004. These early findings do not establish efficacy or the stage of STR-P005.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Starna Therapeutics — official company page
- Starna Therapeutics — supporting primary disclosure
- Starna nearly US$40 million Series B+ — May 11, 2026
- Founding / incorporation disclosure — scope stated in field